CareDx (CDNA) to Release Earnings on Tuesday

CareDx (NASDAQ:CDNA) is expected to be posting its Q1 2026 results after the market closes on Tuesday, April 28th. Analysts expect CareDx to post earnings of $0.13 per share and revenue of $102.2870 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, April 28, 2026 at 4:30 PM ET.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.12). The business had revenue of $108.39 million during the quarter, compared to analysts’ expectations of $102.76 million. CareDx had a negative net margin of 5.65% and a negative return on equity of 6.50%. CareDx’s revenue for the quarter was up 25.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.18 EPS.

CareDx Price Performance

Shares of NASDAQ:CDNA opened at $21.23 on Friday. The business’s 50 day simple moving average is $18.39 and its 200-day simple moving average is $18.10. The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of -53.08 and a beta of 2.54. CareDx has a 12 month low of $10.96 and a 12 month high of $23.24.

Analyst Ratings Changes

A number of research firms recently issued reports on CDNA. BTIG Research upped their target price on CareDx from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Craig Hallum lowered CareDx from a “buy” rating to a “hold” rating and set a $26.00 target price on the stock. in a research note on Tuesday, January 6th. Wall Street Zen raised CareDx from a “hold” rating to a “buy” rating in a research note on Saturday. Weiss Ratings lowered CareDx from a “hold (c-)” rating to a “sell (d)” rating in a research note on Friday, February 27th. Finally, Wells Fargo & Company upped their target price on CareDx from $18.00 to $21.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, CareDx has a consensus rating of “Hold” and an average price target of $27.60.

Insider Transactions at CareDx

In other CareDx news, CEO John Walter Hanna, Jr. sold 10,282 shares of the company’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $21.12, for a total value of $217,155.84. Following the completion of the transaction, the chief executive officer directly owned 676,475 shares of the company’s stock, valued at $14,287,152. This represents a 1.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On CareDx

A number of hedge funds have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD grew its stake in CareDx by 1.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 39,218 shares of the company’s stock worth $739,000 after purchasing an additional 711 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in CareDx by 4.8% in the second quarter. The Manufacturers Life Insurance Company now owns 27,742 shares of the company’s stock worth $542,000 after purchasing an additional 1,280 shares in the last quarter. Quarry LP acquired a new position in CareDx in the fourth quarter worth about $25,000. Franklin Resources Inc. grew its stake in CareDx by 3.8% in the fourth quarter. Franklin Resources Inc. now owns 103,703 shares of the company’s stock worth $1,954,000 after purchasing an additional 3,774 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in CareDx by 120.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,608 shares of the company’s stock worth $149,000 after purchasing an additional 4,160 shares in the last quarter.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.